TICKERNERD
Menu
BHCBHCHealthcare · Drug Manufacturers - Specialty & Generic

BHC Stock Forecast: Bausch Health Cos., Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.86
−3.46% on the day

The 7 Wall Street analysts covering Bausch Health Cos., Inc. hold a median 12-month price target of $7 — +19.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
96 / 100
Median analyst target
$7.00
Analysts covering
7
Revenue$2.9B+12.7% y/y
Operating income$775.0M
Net income$260.0M
Free cash flow$593.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.3%
1M
−6.1%
YTD
−15.7%
1Y
−19.2%
From 52W high
−25.8%
From 52W low
+32.3%
$4.43
$7.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bausch Health Cos., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Accruals
95
Quality
87
Issuance
82
Revisions
75
Growth
67
Volatility
65
Momentum
45
Size
35

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (45): The shares have been drifting down relative to others.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$5.00$6.00$7.00$8.00$9.00Oct 25Jan 26Apr 26Jul 26BHCHigh $9.00Median $7.00Low $6.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
0 Buy7 Hold0 Sell
Low $6.50Median $7.00High $9.00

The green dot is the last close — the median target sits +19.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Apr 2026RBC CapitalMaintainsSector Perform$10 → $9.00
25 Feb 2026BarclaysMaintainsEqual-Weight—
7 Jan 2026Truist SecuritiesMaintainsHold—
9 Dec 2025BarclaysInitiatesEqual-Weight—
2 May 2025RBC CapitalMaintainsSector Perform—
6 Feb 2025JefferiesDowngradeHold—
30 Jan 2025RBC CapitalMaintainsSector Perform—
1 Nov 2024RBC CapitalMaintainsSector Perform—
2 Aug 2024Piper SandlerDowngradeUnderweight—
2 Aug 2024RBC CapitalMaintainsSector Perform—
25 July 2024Truist SecuritiesMaintainsHold—
10 July 2024Raymond JamesInitiatesMarket Perform—
23 Apr 2024RBC CapitalMaintainsSector Perform—
12 Apr 2024RBC CapitalReiteratesSector Perform—
5 Apr 2024RBC CapitalMaintainsSector Perform—
23 Feb 2024RBC CapitalMaintainsSector Perform—
20 Sept 2023JefferiesUpgradeBuy—
16 June 2023TD CowenDowngradeMarket Perform—
22 May 2023JefferiesMaintainsBuy—
5 May 2023RBC CapitalMaintainsSector Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Bausch Health Cos., Inc. returned −19.2% against +17.5% for the S&P 500, dividends included.

BHC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26BHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.2%
Analysts raising
2
Analysts cutting
1
Fundamentals

Bausch Health Cos., Inc. (BHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.3×

Cheaper than 50% of US stocks

Price / sales
0.2×

Cheaper than 93% of US stocks

Price / book
−2.7×

Cheaper than 95% of US stocks

EV / EBITDA
5.7×

Cheaper than 52% of US stocks

Growth & margins
Revenue growth (YoY)
12.7%

Higher than 58% of US stocks

Earnings growth (YoY)
74.3%

Higher than 80% of US stocks

Gross margin
72.9%

Higher than 85% of US stocks

Operating margin
27.2%

Higher than 85% of US stocks

Net margin
−10.1%

Higher than 20% of US stocks

Returns & dividend
Return on equity
41.6%

Higher than 91% of US stocks

Return on assets
6.6%

Higher than 83% of US stocks

Dividend yield
68.3%

Higher than 97% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bausch Health Cos., Inc. (BHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bausch Health Cos., Inc. has a market value of $2.2B and an enterprise value of $22.1B.

  • Revenue in the twelve months to 30 June 2026: $10.9B. The latest quarter grew 12.7% year on year.

  • Net income over the same four quarters: −$1.1B, a −10.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.96.

  • Free cash flow in the twelve months to 30 June 2026: $1.4B.

  • Shares outstanding: 373.9M.

  • Trailing P/E: 13.3×; forward P/E: 1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 68.32%, paying out 0% of earnings.

  • Bausch Health Cos., Inc. employs 20,300 people — $535K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BHCBausch Health Cos., Inc.$2.2B
96
TRLVTrulieve Cannabis Corp.$2.2B
83
ALVOAlvotech$2.1B
29
PBHPrestige Consumer Healthcare, Inc.$2.3B
58
BCRXBioCryst Pharmaceuticals, Inc.$2.0B
87
SUPNSupernus Pharmaceuticals, Inc.$2.4B
79
PRGOPerrigo Co. Plc$1.9B
76

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bausch Health Cos., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BHC news & analysis

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

PRNewsWire · 8 Sept 2026positive

Bausch Health and YUN announced an expansion of their collaboration to bring science-led, microbiome-friendly skincare solutions to Mexico and additional EMEA markets, including the Czech Republic, Slovakia, Ukraine, Bulgaria, and Kazakhstan.

Why it matters — The expansion broadens Bausch Health's market reach for its skincare portfolio into new regions, potentially widening its commercial footprint.

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

PRNewsWire · 27 Aug 2026positive

Bausch Health and its dermatology business, Ortho Dermatologics, announced the recipients of its 2026 Aspire Higher Scholarship Program, awarding scholarships to six students affected by dermatologic conditions.

Why it matters — This highlights Bausch Health's community engagement and patient-focused initiatives within its dermatology segment.

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Business Wire · 24 Aug 2026positive

Bausch + Lomb announced that two of its first-in-class pharmaceutical pipeline assets will advance to new trials based on recent clinical results. CEO Brent Saunders commented that the results support efforts to address challenges patients still face.

Why it matters — For Bausch Health watchers, pipeline progress at its Bausch + Lomb eye health unit signals potential advancement of new therapies.

Can Bausch (BHC) Run Higher on Rising Earnings Estimates?

Zacks Investment Research · 21 Aug 2026positive

Zacks reports that Bausch Health shares have begun gaining and may continue moving higher in the near term, based on solid earnings estimate revisions.

Why it matters — A BHC watcher would care because rising earnings estimate revisions can signal improving expectations for the company's near-term performance.

Bausch (BHC) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 21 Aug 2026positive

Zacks Investment Research upgraded Bausch Health (BHC) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects, which could drive the stock higher in the near term.

Why it matters — A BHC watcher would care because the upgrade reflects improved expectations for the company's earnings outlook.

FAQ

Frequently asked questions about BHC stock

What is the BHC stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Bausch Health Cos., Inc. have a median 12-month price target of $7, with estimates ranging from $6.5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BHC stock a buy right now?

Of the 7 analysts covering Bausch Health Cos., Inc., 0 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bausch Health Cos., Inc. 96 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BHC?

As at 12 Sept 2026, Bausch Health Cos., Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will BHC stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +19.5% from the last close, and Ticker Nerd's factor model ranks Bausch Health Cos., Inc. 96 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BHC stock forecast for 2030?

No analyst covering Bausch Health Cos., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $9 over the next 12 months.

How has BHC stock performed over the past year?

Bausch Health Cos., Inc. returned -19.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bausch Health Cos., Inc. do?

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company focused on developing, manufacturing, and marketing healthcare products across multiple therapeutic areas.

What is the latest news on BHC?

The most recent item we track (PRNewsWire, 8 Sept 2026): "Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets". Bausch Health and YUN announced an expansion of their collaboration to bring science-led, microbiome-friendly skincare solutions to Mexico and additional EMEA markets, including the Czech Republic, Slovakia, Ukraine, Bulgaria, and Kazakhstan.

Company

About Bausch Health Cos., Inc.

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company focused on developing, manufacturing, and marketing healthcare products across multiple therapeutic areas. Bausch Health serves the gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health markets, with a portfolio that includes branded, generic, and over-the-counter medicines as well as medical devices. Its operations are organized around products and services used in treating conditions such as digestive disorders, skin diseases, neurological conditions, and vision-related care. The company also supports hospital and clinic needs through its medical device and ophthalmic businesses. Headquartered in Laval, Quebec, Bausch Health plays a significant role in the global healthcare market by supplying therapies and devices used by patients, physicians, and healthcare providers across the United States and international markets.

CEO Mr. Thomas J. Appio · 20,300 employees · Canada · https://www.bauschhealth.com